| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 33 | 2020 | 1815 | 3.180 |
Why?
|
| Wounds and Injuries | 20 | 2020 | 2400 | 2.330 |
Why?
|
| T-Lymphocytes, Regulatory | 15 | 2022 | 2988 | 1.610 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 4 | 2023 | 495 | 1.360 |
Why?
|
| Immune System | 6 | 2015 | 805 | 1.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 22 | 2021 | 4385 | 1.180 |
Why?
|
| Leukocytes, Mononuclear | 8 | 2023 | 1836 | 1.150 |
Why?
|
| Spleen | 20 | 2020 | 2361 | 1.150 |
Why?
|
| Lymphocyte Activation | 22 | 2021 | 5523 | 1.120 |
Why?
|
| Inflammasomes | 4 | 2022 | 494 | 1.050 |
Why?
|
| Cytokines | 24 | 2022 | 7326 | 1.040 |
Why?
|
| Mesenchymal Stem Cells | 5 | 2023 | 1628 | 1.020 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2015 | 127 | 0.980 |
Why?
|
| Sepsis | 11 | 2021 | 2593 | 0.920 |
Why?
|
| T-Lymphocytes | 19 | 2021 | 10182 | 0.780 |
Why?
|
| Killer Cells, Natural | 2 | 2020 | 2133 | 0.750 |
Why?
|
| Flow Cytometry | 19 | 2022 | 5974 | 0.740 |
Why?
|
| Receptors, Cell Surface | 6 | 2011 | 2867 | 0.730 |
Why?
|
| Immunophenotyping | 11 | 2023 | 1880 | 0.720 |
Why?
|
| Th1 Cells | 16 | 2021 | 1057 | 0.710 |
Why?
|
| Th2 Cells | 12 | 2016 | 1061 | 0.700 |
Why?
|
| Superantigens | 4 | 2004 | 129 | 0.680 |
Why?
|
| Systemic Inflammatory Response Syndrome | 5 | 2020 | 611 | 0.670 |
Why?
|
| Mice | 80 | 2023 | 81178 | 0.650 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 805 | 0.640 |
Why?
|
| Wound Infection | 2 | 2019 | 242 | 0.620 |
Why?
|
| CD8-Positive T-Lymphocytes | 13 | 2023 | 4477 | 0.620 |
Why?
|
| Interleukin-10 | 11 | 2012 | 1200 | 0.570 |
Why?
|
| Enterotoxins | 6 | 2011 | 368 | 0.570 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2019 | 1838 | 0.560 |
Why?
|
| Neutrophils | 12 | 2023 | 3717 | 0.540 |
Why?
|
| Animals | 96 | 2023 | 168788 | 0.540 |
Why?
|
| Monocytes | 7 | 2019 | 2594 | 0.540 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2015 | 708 | 0.520 |
Why?
|
| Adjuvants, Immunologic | 2 | 2015 | 1001 | 0.520 |
Why?
|
| Neutropenia | 1 | 2020 | 895 | 0.520 |
Why?
|
| Caspase 1 | 2 | 2014 | 224 | 0.500 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 2 | 2011 | 67 | 0.490 |
Why?
|
| Interleukin-1 | 9 | 2005 | 1263 | 0.490 |
Why?
|
| Immunologic Memory | 2 | 2020 | 1348 | 0.480 |
Why?
|
| Membrane Glycoproteins | 7 | 2011 | 3769 | 0.480 |
Why?
|
| Lymph Nodes | 9 | 2020 | 3469 | 0.470 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 342 | 0.460 |
Why?
|
| Macrophages | 12 | 2023 | 5657 | 0.460 |
Why?
|
| Breeding | 1 | 2012 | 51 | 0.450 |
Why?
|
| Lupus Nephritis | 3 | 2022 | 310 | 0.440 |
Why?
|
| Interferon-gamma | 17 | 2022 | 3203 | 0.440 |
Why?
|
| Immunity, Innate | 11 | 2015 | 2958 | 0.430 |
Why?
|
| Mice, Inbred C57BL | 28 | 2023 | 21824 | 0.410 |
Why?
|
| Arthritis, Rheumatoid | 8 | 2021 | 3712 | 0.390 |
Why?
|
| Interleukin-2 | 13 | 2015 | 1904 | 0.390 |
Why?
|
| Disease Models, Animal | 21 | 2020 | 18027 | 0.380 |
Why?
|
| Lymphocytes | 5 | 2020 | 2617 | 0.370 |
Why?
|
| Inflammation | 14 | 2021 | 10634 | 0.370 |
Why?
|
| Shock | 1 | 2012 | 318 | 0.360 |
Why?
|
| Signal Transduction | 12 | 2019 | 23404 | 0.360 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2006 | 573 | 0.350 |
Why?
|
| HMGA1a Protein | 2 | 2021 | 64 | 0.350 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2019 | 986 | 0.340 |
Why?
|
| Dendritic Cells | 6 | 2012 | 2725 | 0.340 |
Why?
|
| Radiation Injuries | 2 | 2014 | 1178 | 0.330 |
Why?
|
| Leukocytes | 7 | 2022 | 2040 | 0.330 |
Why?
|
| Lipopolysaccharides | 12 | 2021 | 2216 | 0.330 |
Why?
|
| Enzyme Activation | 4 | 2014 | 3701 | 0.330 |
Why?
|
| Cell Proliferation | 11 | 2023 | 10480 | 0.320 |
Why?
|
| Forkhead Transcription Factors | 3 | 2011 | 1613 | 0.310 |
Why?
|
| Antigen Presentation | 5 | 2010 | 1284 | 0.310 |
Why?
|
| Synovial Membrane | 3 | 2019 | 507 | 0.300 |
Why?
|
| Interleukins | 4 | 2022 | 791 | 0.300 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2023 | 1596 | 0.290 |
Why?
|
| Gene Expression Regulation | 12 | 2019 | 12075 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2018 | 4419 | 0.280 |
Why?
|
| Ovalbumin | 3 | 2003 | 719 | 0.270 |
Why?
|
| Hemorrhage | 4 | 2019 | 3461 | 0.270 |
Why?
|
| Immunity | 4 | 2020 | 1012 | 0.270 |
Why?
|
| Escherichia coli Infections | 2 | 2018 | 532 | 0.270 |
Why?
|
| B-Lymphocytes | 5 | 2019 | 4665 | 0.260 |
Why?
|
| Antibody Formation | 5 | 2020 | 1402 | 0.260 |
Why?
|
| Toll-Like Receptors | 5 | 2009 | 592 | 0.250 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2012 | 1018 | 0.250 |
Why?
|
| Male | 63 | 2022 | 350027 | 0.250 |
Why?
|
| Synovial Fluid | 3 | 2022 | 394 | 0.250 |
Why?
|
| Phenotype | 6 | 2022 | 16365 | 0.250 |
Why?
|
| Phagocytosis | 7 | 2021 | 1538 | 0.240 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2011 | 2540 | 0.240 |
Why?
|
| Mice, Transgenic | 10 | 2021 | 9735 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 11 | 2021 | 6386 | 0.220 |
Why?
|
| Adoptive Transfer | 4 | 2021 | 844 | 0.220 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2023 | 111 | 0.210 |
Why?
|
| Keratitis | 2 | 2016 | 268 | 0.210 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 625 | 0.210 |
Why?
|
| Toll-Like Receptor 4 | 5 | 2008 | 567 | 0.210 |
Why?
|
| Sialoglycoproteins | 2 | 1994 | 318 | 0.210 |
Why?
|
| Respiratory Burst | 2 | 2023 | 113 | 0.210 |
Why?
|
| Culture Media, Conditioned | 1 | 2023 | 534 | 0.210 |
Why?
|
| Inflammation Mediators | 3 | 2008 | 1889 | 0.200 |
Why?
|
| Antigens | 3 | 2003 | 1466 | 0.200 |
Why?
|
| NF-kappa B | 3 | 2018 | 2501 | 0.200 |
Why?
|
| Purines | 2 | 2022 | 594 | 0.200 |
Why?
|
| Interleukin-4 | 8 | 1998 | 1147 | 0.200 |
Why?
|
| Chemokine CXCL12 | 2 | 2021 | 464 | 0.200 |
Why?
|
| Genes, Dominant | 2 | 2021 | 880 | 0.190 |
Why?
|
| Shock, Septic | 2 | 2005 | 775 | 0.190 |
Why?
|
| Interleukin-17 | 2 | 2017 | 900 | 0.180 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2023 | 182 | 0.180 |
Why?
|
| Mice, Inbred A | 5 | 2001 | 248 | 0.180 |
Why?
|
| Up-Regulation | 4 | 2012 | 4217 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 2103 | 0.180 |
Why?
|
| Multiple Trauma | 1 | 2023 | 367 | 0.180 |
Why?
|
| Mice, Knockout | 12 | 2021 | 14556 | 0.180 |
Why?
|
| Isoquinolines | 1 | 2021 | 368 | 0.180 |
Why?
|
| Trophoblasts | 1 | 2021 | 215 | 0.180 |
Why?
|
| Cells, Cultured | 19 | 2021 | 19227 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2023 | 542 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2019 | 71 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2020 | 1475 | 0.180 |
Why?
|
| Gene Expression Profiling | 8 | 2019 | 9438 | 0.180 |
Why?
|
| Transcription Factor AP-1 | 1 | 2001 | 317 | 0.180 |
Why?
|
| Epitopes | 2 | 2020 | 2571 | 0.180 |
Why?
|
| Epitope Mapping | 1 | 2020 | 311 | 0.170 |
Why?
|
| Technology | 1 | 2022 | 304 | 0.170 |
Why?
|
| Aortic Diseases | 2 | 2016 | 742 | 0.170 |
Why?
|
| Autoimmunity | 3 | 2023 | 1349 | 0.170 |
Why?
|
| Lung Injury | 2 | 2020 | 436 | 0.170 |
Why?
|
| Arthritis, Experimental | 1 | 2021 | 291 | 0.170 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 732 | 0.170 |
Why?
|
| Antigen-Presenting Cells | 5 | 2012 | 973 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2007 | 1708 | 0.170 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 2422 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2001 | 390 | 0.170 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 121 | 0.170 |
Why?
|
| Fibroblasts | 5 | 2019 | 4156 | 0.160 |
Why?
|
| Receptors, Purinergic P2X4 | 1 | 2018 | 22 | 0.160 |
Why?
|
| Immunotherapy | 4 | 2022 | 4440 | 0.160 |
Why?
|
| Nasal Polyps | 1 | 2023 | 360 | 0.160 |
Why?
|
| Immunoglobulin G | 3 | 2020 | 4559 | 0.160 |
Why?
|
| Receptors, LDL | 3 | 2016 | 475 | 0.160 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 972 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 323 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2021 | 349 | 0.160 |
Why?
|
| Interleukin-12 | 6 | 2000 | 579 | 0.160 |
Why?
|
| Cell Polarity | 1 | 2021 | 645 | 0.160 |
Why?
|
| Hyperoxia | 1 | 2020 | 262 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 380 | 0.150 |
Why?
|
| Autocrine Communication | 1 | 2018 | 171 | 0.150 |
Why?
|
| Injury Severity Score | 2 | 2017 | 1013 | 0.150 |
Why?
|
| Transgenes | 1 | 2021 | 1009 | 0.150 |
Why?
|
| Humans | 65 | 2023 | 744220 | 0.150 |
Why?
|
| CD4-CD8 Ratio | 1 | 2016 | 112 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 821 | 0.150 |
Why?
|
| Time Factors | 10 | 2020 | 40063 | 0.140 |
Why?
|
| Plasma | 1 | 2020 | 575 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2015 | 310 | 0.140 |
Why?
|
| Atherosclerosis | 4 | 2016 | 3444 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2019 | 675 | 0.140 |
Why?
|
| Arthritis | 1 | 2022 | 659 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 9275 | 0.140 |
Why?
|
| Protein Kinase C | 2 | 2011 | 1227 | 0.140 |
Why?
|
| Chemokine CCL2 | 2 | 2017 | 617 | 0.140 |
Why?
|
| Oncolytic Virotherapy | 1 | 2022 | 497 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 780 | 0.140 |
Why?
|
| Rhinitis | 1 | 2023 | 691 | 0.140 |
Why?
|
| Nitric Oxide | 1 | 2005 | 2131 | 0.140 |
Why?
|
| Receptors, Interleukin-1 | 2 | 1994 | 262 | 0.130 |
Why?
|
| Glioblastoma | 2 | 2022 | 3481 | 0.130 |
Why?
|
| Receptors, Chemokine | 2 | 2017 | 669 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 2 | 2008 | 424 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 3921 | 0.130 |
Why?
|
| Eye Infections, Fungal | 1 | 2016 | 110 | 0.130 |
Why?
|
| Incineration | 1 | 2014 | 20 | 0.130 |
Why?
|
| Acetylglucosamine | 1 | 2016 | 191 | 0.130 |
Why?
|
| Recycling | 1 | 2014 | 17 | 0.130 |
Why?
|
| Interleukin-6 | 5 | 2021 | 3201 | 0.130 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1995 | 248 | 0.130 |
Why?
|
| Antilymphocyte Serum | 1 | 2016 | 492 | 0.130 |
Why?
|
| Immunity, Cellular | 2 | 2016 | 1607 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2018 | 2025 | 0.120 |
Why?
|
| Sinusitis | 1 | 2023 | 923 | 0.120 |
Why?
|
| Dexamethasone | 1 | 2022 | 1948 | 0.120 |
Why?
|
| CLOCK Proteins | 1 | 2014 | 87 | 0.120 |
Why?
|
| Neutrophil Activation | 2 | 2021 | 186 | 0.120 |
Why?
|
| Toll-Like Receptor 2 | 3 | 2008 | 354 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 5 | 2007 | 6172 | 0.120 |
Why?
|
| Cattle | 6 | 1994 | 3922 | 0.120 |
Why?
|
| Cell Death | 2 | 2021 | 1708 | 0.120 |
Why?
|
| Drug Industry | 1 | 2020 | 745 | 0.110 |
Why?
|
| Fibrosarcoma | 2 | 2010 | 348 | 0.110 |
Why?
|
| Th17 Cells | 1 | 2020 | 766 | 0.110 |
Why?
|
| Lung | 7 | 2023 | 9852 | 0.110 |
Why?
|
| Endotoxins | 2 | 2014 | 527 | 0.110 |
Why?
|
| Tears | 1 | 2014 | 256 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 876 | 0.110 |
Why?
|
| Antibodies | 2 | 2023 | 2461 | 0.110 |
Why?
|
| Conservation of Natural Resources | 1 | 2014 | 205 | 0.110 |
Why?
|
| Female | 33 | 2022 | 380197 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 945 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2022 | 2108 | 0.110 |
Why?
|
| Whole-Body Irradiation | 1 | 2012 | 449 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 2136 | 0.100 |
Why?
|
| Eye Infections, Bacterial | 1 | 2014 | 235 | 0.100 |
Why?
|
| Gamma Rays | 1 | 2012 | 320 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 1352 | 0.100 |
Why?
|
| Antigens, Surface | 2 | 2011 | 1663 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2020 | 2069 | 0.100 |
Why?
|
| Cell Differentiation | 8 | 2022 | 11478 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 3385 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2003 | 5096 | 0.100 |
Why?
|
| Lymphocyte Depletion | 3 | 2011 | 608 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 3 | 2021 | 297 | 0.100 |
Why?
|
| Cell Separation | 3 | 2019 | 1751 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2021 | 21752 | 0.090 |
Why?
|
| Zinc | 1 | 2014 | 683 | 0.090 |
Why?
|
| Heme Oxygenase-1 | 1 | 2013 | 381 | 0.090 |
Why?
|
| Proteomics | 1 | 2023 | 3637 | 0.090 |
Why?
|
| Streptococcus pneumoniae | 1 | 2015 | 714 | 0.090 |
Why?
|
| Databases, Genetic | 2 | 2014 | 1782 | 0.090 |
Why?
|
| Cornea | 2 | 2016 | 1524 | 0.090 |
Why?
|
| Middle Aged | 17 | 2021 | 213367 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 8860 | 0.090 |
Why?
|
| Interleukin-5 | 2 | 2023 | 273 | 0.090 |
Why?
|
| HLA-DR Antigens | 2 | 2023 | 645 | 0.090 |
Why?
|
| Single-Cell Analysis | 4 | 2021 | 2183 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 3176 | 0.090 |
Why?
|
| Cell Survival | 2 | 2021 | 5881 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2759 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2019 | 1885 | 0.080 |
Why?
|
| Cell Movement | 2 | 2018 | 5216 | 0.080 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 3584 | 0.080 |
Why?
|
| Uric Acid | 1 | 2014 | 765 | 0.080 |
Why?
|
| NFATC Transcription Factors | 1 | 2011 | 381 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 430 | 0.080 |
Why?
|
| Gene Expression | 5 | 2019 | 7799 | 0.080 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 1971 | 0.080 |
Why?
|
| Myeloid Cells | 3 | 2020 | 809 | 0.080 |
Why?
|
| Antibodies, Blocking | 2 | 2011 | 254 | 0.080 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 77 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2204 | 0.080 |
Why?
|
| Receptors, CXCR5 | 2 | 2019 | 92 | 0.080 |
Why?
|
| Lymphocyte Antigen 96 | 2 | 2008 | 19 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 527 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2006 | 4752 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 791 | 0.080 |
Why?
|
| Survival Rate | 5 | 2013 | 12781 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 2732 | 0.080 |
Why?
|
| Ascitic Fluid | 1 | 2008 | 192 | 0.080 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 713 | 0.080 |
Why?
|
| Cecum | 3 | 2013 | 237 | 0.080 |
Why?
|
| Kidney | 2 | 2022 | 7183 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2016 | 7879 | 0.070 |
Why?
|
| Cell Communication | 3 | 2019 | 1621 | 0.070 |
Why?
|
| Haemophilus | 1 | 1987 | 27 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 1989 | 286 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2886 | 0.070 |
Why?
|
| Immune Tolerance | 3 | 2020 | 2258 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2011 | 1726 | 0.070 |
Why?
|
| Cell Division | 3 | 2003 | 4567 | 0.070 |
Why?
|
| Adult | 17 | 2021 | 214035 | 0.070 |
Why?
|
| Immunity, Active | 1 | 2005 | 60 | 0.070 |
Why?
|
| Bacteremia | 1 | 2013 | 962 | 0.070 |
Why?
|
| Selenium | 1 | 1989 | 405 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 1992 | 1423 | 0.070 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2014 | 808 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 1157 | 0.070 |
Why?
|
| Environmental Pollutants | 1 | 2014 | 1180 | 0.070 |
Why?
|
| Pneumonia | 2 | 2014 | 2134 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2021 | 767 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2021 | 3747 | 0.060 |
Why?
|
| Mitochondria | 1 | 2018 | 3520 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 1782 | 0.060 |
Why?
|
| Macrophage Activation | 1 | 2008 | 558 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 389 | 0.060 |
Why?
|
| MyoD Protein | 1 | 2005 | 151 | 0.060 |
Why?
|
| Shock, Traumatic | 1 | 2004 | 22 | 0.060 |
Why?
|
| Abdominal Injuries | 1 | 2008 | 352 | 0.060 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 906 | 0.060 |
Why?
|
| Adaptation, Physiological | 2 | 2003 | 1312 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 4837 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 1039 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2017 | 3680 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2019 | 1341 | 0.060 |
Why?
|
| Molecular Sequence Data | 6 | 2003 | 18116 | 0.060 |
Why?
|
| Antibody-Producing Cells | 1 | 2023 | 143 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2014 | 13036 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2023 | 128 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2007 | 661 | 0.060 |
Why?
|
| Binding, Competitive | 2 | 1995 | 1159 | 0.060 |
Why?
|
| Antigens, CD | 3 | 2006 | 4026 | 0.060 |
Why?
|
| Peptidoglycan | 1 | 2005 | 246 | 0.060 |
Why?
|
| Interleukin-15 | 1 | 2023 | 184 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 2624 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 1284 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15538 | 0.050 |
Why?
|
| Mice, Inbred Strains | 3 | 2003 | 1827 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 2013 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2012 | 10250 | 0.050 |
Why?
|
| Antigens, Ly | 1 | 2003 | 291 | 0.050 |
Why?
|
| Transcription, Genetic | 4 | 2001 | 7723 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 916 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 644 | 0.050 |
Why?
|
| Metabolism | 1 | 2003 | 193 | 0.050 |
Why?
|
| Concanavalin A | 1 | 2001 | 191 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2023 | 473 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2014 | 5021 | 0.050 |
Why?
|
| Annual Reports as Topic | 1 | 2020 | 33 | 0.050 |
Why?
|
| Homeostasis | 1 | 2012 | 3339 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2006 | 2008 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2021 | 365 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 1525 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2000 | 159 | 0.050 |
Why?
|
| Lipoproteins, LDL | 2 | 2016 | 639 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2022 | 683 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 644 | 0.050 |
Why?
|
| Skin | 1 | 1994 | 4363 | 0.050 |
Why?
|
| Vidarabine | 1 | 2021 | 345 | 0.050 |
Why?
|
| Quinazolinones | 1 | 2022 | 221 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2006 | 1355 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 1677 | 0.040 |
Why?
|
| RANK Ligand | 1 | 2021 | 326 | 0.040 |
Why?
|
| Mutation | 2 | 2023 | 29784 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3871 | 0.040 |
Why?
|
| Mice, Inbred C3H | 3 | 2008 | 964 | 0.040 |
Why?
|
| Proteinuria | 1 | 2022 | 657 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2003 | 880 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2020 | 240 | 0.040 |
Why?
|
| Lymphocyte Subsets | 2 | 1997 | 315 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 1996 | 5867 | 0.040 |
Why?
|
| Imidazoles | 1 | 2005 | 1206 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2020 | 841 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2021 | 390 | 0.040 |
Why?
|
| Chemokines | 1 | 2022 | 969 | 0.040 |
Why?
|
| Genomics | 1 | 2014 | 5722 | 0.040 |
Why?
|
| Phytohemagglutinins | 1 | 1997 | 170 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 840 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2005 | 1639 | 0.040 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 1997 | 68 | 0.040 |
Why?
|
| Species Specificity | 2 | 1994 | 2480 | 0.040 |
Why?
|
| Macrophage-Activating Factors | 1 | 2017 | 21 | 0.040 |
Why?
|
| Freund's Adjuvant | 1 | 1997 | 139 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2021 | 729 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 3047 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2020 | 573 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2010 | 6367 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1997 | 158 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2017 | 54 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 56436 | 0.040 |
Why?
|
| Endotoxemia | 1 | 2018 | 206 | 0.040 |
Why?
|
| Computational Biology | 2 | 2019 | 3523 | 0.040 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1998 | 274 | 0.040 |
Why?
|
| Clone Cells | 3 | 1998 | 1692 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2018 | 743 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6489 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2003 | 3689 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 528 | 0.040 |
Why?
|
| Ligation | 1 | 1997 | 453 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2019 | 2715 | 0.040 |
Why?
|
| Base Sequence | 4 | 1996 | 12801 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 1655 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 809 | 0.040 |
Why?
|
| Transcription Factors | 1 | 1996 | 12207 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 193 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 2085 | 0.030 |
Why?
|
| Ionomycin | 1 | 1996 | 109 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 1 | 1996 | 199 | 0.030 |
Why?
|
| Ethidium | 1 | 1995 | 27 | 0.030 |
Why?
|
| RNA Ligase (ATP) | 1 | 1995 | 9 | 0.030 |
Why?
|
| Cholesterol, VLDL | 1 | 2015 | 65 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 1451 | 0.030 |
Why?
|
| Mast Cells | 1 | 2003 | 1544 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 2236 | 0.030 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2012 | 319 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2003 | 13817 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 1997 | 2050 | 0.030 |
Why?
|
| Interferons | 1 | 2019 | 706 | 0.030 |
Why?
|
| Templates, Genetic | 1 | 1995 | 211 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2003 | 1404 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2015 | 148 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2006 | 2508 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2021 | 40992 | 0.030 |
Why?
|
| Eosinophilia | 2 | 2015 | 542 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2020 | 1275 | 0.030 |
Why?
|
| Circadian Rhythm Signaling Peptides and Proteins | 1 | 2014 | 30 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 1368 | 0.030 |
Why?
|
| Immunization | 1 | 1999 | 1256 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 821 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 2001 | 1026 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 1996 | 275 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2021 | 1299 | 0.030 |
Why?
|
| Workflow | 1 | 2019 | 847 | 0.030 |
Why?
|
| Child | 7 | 2023 | 77679 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 3800 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2018 | 687 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1996 | 1581 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2015 | 374 | 0.030 |
Why?
|
| Adipocytes | 1 | 2021 | 1182 | 0.030 |
Why?
|
| Reference Values | 2 | 1999 | 4982 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2003 | 3748 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1999 | 1171 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2018 | 670 | 0.030 |
Why?
|
| Cell Line | 4 | 1996 | 15999 | 0.030 |
Why?
|
| Pyridines | 1 | 2005 | 2822 | 0.030 |
Why?
|
| Neoplasms | 3 | 2011 | 21672 | 0.030 |
Why?
|
| RNA | 3 | 2005 | 2749 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 907 | 0.030 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1992 | 97 | 0.030 |
Why?
|
| Granulocytes | 1 | 2014 | 547 | 0.030 |
Why?
|
| Endothelium | 1 | 1995 | 778 | 0.030 |
Why?
|
| Toxoplasmosis | 1 | 1993 | 91 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2020 | 4012 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2018 | 1126 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1994 | 1101 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 12961 | 0.030 |
Why?
|
| Hypotension | 1 | 2018 | 880 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 1677 | 0.030 |
Why?
|
| Toxoplasma | 1 | 1993 | 150 | 0.030 |
Why?
|
| Genome, Human | 1 | 2005 | 4420 | 0.030 |
Why?
|
| Antibodies, Protozoan | 1 | 1993 | 253 | 0.030 |
Why?
|
| Aspirin | 1 | 2023 | 3282 | 0.020 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2011 | 29 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1997 | 1463 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2000 | 1401 | 0.020 |
Why?
|
| Apoptosis | 3 | 2016 | 9728 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 5529 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2023 | 3703 | 0.020 |
Why?
|
| Airway Resistance | 1 | 2012 | 404 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2023 | 2940 | 0.020 |
Why?
|
| DNA Primers | 1 | 1995 | 2892 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2022 | 53280 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2018 | 6612 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 1978 | 0.020 |
Why?
|
| China | 1 | 2016 | 2247 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 25043 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2014 | 1584 | 0.020 |
Why?
|
| Immunogenetic Phenomena | 1 | 2010 | 23 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 1620 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1994 | 1032 | 0.020 |
Why?
|
| Genes, Mitochondrial | 1 | 2010 | 61 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 1996 | 5853 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3085 | 0.020 |
Why?
|
| Infant | 4 | 2021 | 35129 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2003 | 3123 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 16687 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2010 | 291 | 0.020 |
Why?
|
| Food Additives | 1 | 1989 | 19 | 0.020 |
Why?
|
| DNA-Binding Proteins | 3 | 1996 | 9647 | 0.020 |
Why?
|
| Aged | 7 | 2021 | 163253 | 0.020 |
Why?
|
| Kinetics | 2 | 1994 | 6474 | 0.020 |
Why?
|
| General Surgery | 1 | 2020 | 1636 | 0.020 |
Why?
|
| Adolescent | 6 | 2021 | 85759 | 0.020 |
Why?
|
| Liver | 1 | 2004 | 7472 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9147 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2021 | 4220 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2020 | 3741 | 0.020 |
Why?
|
| Environment | 1 | 2014 | 1124 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 5169 | 0.020 |
Why?
|
| Stem Cells | 1 | 2021 | 3567 | 0.020 |
Why?
|
| Zymosan | 1 | 2008 | 124 | 0.020 |
Why?
|
| Europe | 1 | 2014 | 3339 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2453 | 0.020 |
Why?
|
| Aorta | 1 | 2015 | 2061 | 0.020 |
Why?
|
| Culture Media | 1 | 1989 | 908 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2021 | 4289 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1989 | 2255 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6757 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2019 | 3690 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1996 | 2440 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1996 | 2969 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3598 | 0.020 |
Why?
|
| Binding Sites | 1 | 1995 | 6116 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 902 | 0.020 |
Why?
|
| Trans-Activators | 1 | 1996 | 2924 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 480 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 489 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 452 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 1574 | 0.020 |
Why?
|
| Superoxides | 1 | 1987 | 387 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 3023 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 2171 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 2513 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 697 | 0.020 |
Why?
|
| Incidence | 1 | 2022 | 20945 | 0.020 |
Why?
|
| Risk | 1 | 2016 | 9685 | 0.020 |
Why?
|
| Phosphorylation | 1 | 1995 | 8437 | 0.010 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 1519 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 1151 | 0.010 |
Why?
|
| Rats | 2 | 1997 | 24273 | 0.010 |
Why?
|
| Acute Disease | 1 | 2014 | 7148 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1821 | 0.010 |
Why?
|
| Genotype | 2 | 2011 | 12956 | 0.010 |
Why?
|
| Platelet Count | 1 | 2006 | 781 | 0.010 |
Why?
|
| Aging | 1 | 2022 | 8661 | 0.010 |
Why?
|
| Peritoneal Diseases | 1 | 2003 | 75 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2763 | 0.010 |
Why?
|
| Microarray Analysis | 1 | 2005 | 766 | 0.010 |
Why?
|
| United States | 2 | 2020 | 69867 | 0.010 |
Why?
|
| Principal Component Analysis | 1 | 2005 | 940 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2012 | 1796 | 0.010 |
Why?
|
| Abdomen | 1 | 2008 | 1118 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1993 | 4455 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11493 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 3001 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2005 | 694 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 2715 | 0.010 |
Why?
|
| Asthma | 1 | 1998 | 6011 | 0.010 |
Why?
|
| Prevalence | 1 | 2016 | 15226 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4407 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 1998 | 233 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8628 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1998 | 210 | 0.010 |
Why?
|
| Proteins | 1 | 1992 | 6101 | 0.010 |
Why?
|
| Age Factors | 2 | 2010 | 18367 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1998 | 421 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 57768 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1975 | 5755 | 0.010 |
Why?
|
| Software | 1 | 2010 | 4442 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1997 | 1161 | 0.010 |
Why?
|
| Deoxyribonucleoproteins | 1 | 1994 | 3 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2010 | 5102 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 13096 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 4776 | 0.010 |
Why?
|
| CHO Cells | 1 | 1997 | 1407 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1993 | 107 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 13990 | 0.010 |
Why?
|
| Ischemia | 1 | 2003 | 1914 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 768 | 0.010 |
Why?
|
| Brain | 1 | 2020 | 26413 | 0.010 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 1993 | 67 | 0.010 |
Why?
|
| Cricetinae | 1 | 1997 | 2472 | 0.010 |
Why?
|
| Eyeglasses | 1 | 1954 | 145 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39045 | 0.010 |
Why?
|
| Azacitidine | 1 | 1994 | 347 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 4216 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 2839 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1993 | 448 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1997 | 2256 | 0.010 |
Why?
|
| Methylation | 1 | 1994 | 1108 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 63119 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 4321 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1995 | 1155 | 0.010 |
Why?
|
| Viscera | 1 | 1951 | 139 | 0.010 |
Why?
|
| Adrenal Cortex | 1 | 1951 | 140 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 1951 | 284 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1994 | 794 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20123 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1999 | 1269 | 0.010 |
Why?
|
| Genes | 1 | 1994 | 1893 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 14726 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1993 | 786 | 0.010 |
Why?
|
| Israel | 1 | 1993 | 796 | 0.010 |
Why?
|
| Emigration and Immigration | 1 | 1993 | 404 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2003 | 4399 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 29050 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2505 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1993 | 1267 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1993 | 2007 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 19907 | 0.000 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1954 | 2234 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 11368 | 0.000 |
Why?
|
| Bacteria | 1 | 1996 | 2114 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1951 | 1172 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1996 | 10949 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1989 | 15161 | 0.000 |
Why?
|
| Rural Population | 1 | 1993 | 2210 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 1993 | 7784 | 0.000 |
Why?
|
| Sex Factors | 1 | 1993 | 10396 | 0.000 |
Why?
|